A Phase I Clinical Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of F01 in Patients With Moderate-to-severe Refractory Systemic Lupus Erythematosus
Latest Information Update: 24 Jun 2024
At a glance
- Drugs Anti-CD19-CAR-Engineered-NK-cells-therapy-Shanghai-Simnova-Biotechnology (Primary) ; Cyclophosphamide; Fludarabine
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Shanghai Simnova Biotechnology
- 24 Jun 2024 New trial record